Giredestrant showed invasive disease-free survival benefits across menopausal status in lidERA, a randomized trial in high-risk stage I–III ER+/HER2− early breast cancer. The study compared adjuvant giredestrant 30 mg daily with tamoxifen or an aromatase inhibitor (± ovarian function suppression), with iDFS as the primary endpoint. Results presented included hazard ratios favoring giredestrant in premenopausal and postmenopausal subgroups, alongside reductions in treatment discontinuation driven by musculoskeletal pain versus standard endocrine therapy. The oral selective estrogen receptor degrader is designed to improve ER blockade without fulvestrant’s IV administration. Queen Mary University of London’s Peter Schmid highlighted that the iDFS benefit appeared irrespective of menopausal status, adding evidence for oral SERD positioning in adjuvant endocrine therapy.